Aceclidine
- Generic Name
- Aceclidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15NO2
- CAS Number
- 827-61-2
- Unique Ingredient Identifier
- 0578K3ELIO
- Background
Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.
- Indication
滴眼给药用于青光眼。
- Associated Conditions
- -
- Associated Therapies
- -
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- LENZ Therapeutics, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT05936489
- Locations
- 🇺🇸
Site #101, Newport Beach, California, United States
Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- LENZ Therapeutics, Inc
- Target Recruit Count
- 229
- Registration Number
- NCT05728944
- Locations
- 🇺🇸
Site #215, Bozeman, Montana, United States
🇺🇸Site #216, Scottsdale, Arizona, United States
🇺🇸Site #209, Dothan, Alabama, United States
Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- LENZ Therapeutics, Inc
- Target Recruit Count
- 469
- Registration Number
- NCT05656027
- Locations
- 🇺🇸
Site #121, Mesa, Arizona, United States
🇺🇸Site #104, Fargo, North Dakota, United States
🇺🇸Site #122, Phoenix, Arizona, United States
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- LENZ Therapeutics, Inc
- Target Recruit Count
- 58
- Registration Number
- NCT03201562
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath